Search

Boehringer Ingelheim and Lilly announce positive top-line Phase III data results for empagliflozin as adjunct to insulin in type 1 diabetes

Boehringer Ingelheim and Lilly Partner with Duke Clinical Research Institute to Advance Multidisciplinary Care for People with Type 2 Diabetes and Cardiovascular Disease

US FDA approves the Cyltezo® Pen, a new autoinjector option, ahead of July 1 commercial launch

FDA Grants Priority Review to Boehringer Ingelheim’s Biologics License Application for Idarucizumab*

Efficacy and safety of Ofev® (nintedanib) reinforced in new presentations at ATS 2018

US FDA grants Fast Track designation to Jardiance® (empagliflozin) to improve outcomes following a heart attack

Boehringer Ingelheim and Lilly expand heart failure program for Jardiance with new exercise capacity trials

Full data announced in phase III EMPA-KIDNEY trial

The EMPA-KIDNEY phase III clinical trial met its primary endpoint by demonstrating a significant kidney and cardiovascular benefit for adults living with chronic kidney disease (CKD)

Jardiance® reduced the risk of first plus recurrent cardiovascular events in adults with type 2 diabetes and established cardiovascular disease in new analysis from the EMPA-REG OUTCOME® trial

New Jardiance® findings showed improved cardio-renal outcomes in adults with heart failure with reduced ejection fraction regardless of chronic kidney disease status

Top-line Phase II Data for treatment of MASH

Boehringer Ingelheim and Zealand Pharma announced top-line Phase II data for treatment of metabolic dysfuntion-associated steatohepatitis (MASH).

FDA Provides Full Approval to Praxbind, Specific Reversal Agent for Pradaxa

Boehringer Ingelheim announces comprehensive settlement of U.S. Pradaxa® (dabigatran etexilate mesylate) litigation

Boehringer Ingelheim and Lilly announce the CAROLINA cardiovascular outcome trial of Tradjenta met its primary endpoint of non-inferiority compared with glimepiride

U.S. FDA Grants Fast Track Designation to Empagliflozin for the Treatment of Chronic Heart Failure

Health disparities in Black and African Americans

Addressing social determinants of health in cardio-kidney-metabolic care

Jardiance shows consistent cardio-renal benefits in adults with heart failure with left ventricular ejection fraction over 40% regardless of chronic kidney disease status

Improving Access to Clinical Trials

Walgreens and Boehringer Ingelheim Are Partnering to Improve Diversity in Clinical Trials

Diabetes

Boehringer Ingelheim grows faster than the pharmaceutical market for the tenth time in succession / continued high level of investment in research and development / market launch of five innovative medicines planned

Boehringer Ingelheim grows faster than the pharmaceutical market for the tenth time in succession / continued high level of investment in research and development / market launch of five innovative medicines planned

Boehringer Ingelheim and OSE Immunotherapeutics Announce Global Immuno-Oncology Partnership to Develop a Pioneering Checkpoint Inhibitor for the Treatment of Advanced Solid Tumors

FDA Approves Praxbind® (idarucizumab), Specific Reversal Agent for Pradaxa® (dabigatran etexilate mesylate)

Jardiance® reduced risk of cardiovascular death in adults with type 2 diabetes and peripheral artery disease

IPF patients treated with Ofev® (nintedanib) versus placebo were twice as likely to have improved or stable lung function

PetPro Connect: Veterinary Medicine in the Digital Age

Read more on PetPro Connect - the BI app & web portal, linking pet owners and veterinarians in a world transformed by digital health and new medicine.

About Us

Human Health

Animal Health

Science & Innovation

Partnering

Careers

Search

Boehringer Ingelheim and Lilly announce positive top-line Phase III data results for empagliflozin as adjunct to insulin in type 1 diabetes

Boehringer Ingelheim and Lilly Partner with Duke Clinical Research Institute to Advance Multidisciplinary Care for People with Type 2 Diabetes and Cardiovascular Disease

US FDA approves the Cyltezo® Pen, a new autoinjector option, ahead of July 1 commercial launch

FDA Grants Priority Review to Boehringer Ingelheim’s Biologics License Application for Idarucizumab*

Efficacy and safety of Ofev® (nintedanib) reinforced in new presentations at ATS 2018

US FDA grants Fast Track designation to Jardiance® (empagliflozin) to improve outcomes following a heart attack

Boehringer Ingelheim and Lilly expand heart failure program for Jardiance with new exercise capacity trials

Full data announced in phase III EMPA-KIDNEY trial

Jardiance® reduced the risk of first plus recurrent cardiovascular events in adults with type 2 diabetes and established cardiovascular disease in new analysis from the EMPA-REG OUTCOME® trial

New Jardiance® findings showed improved cardio-renal outcomes in adults with heart failure with reduced ejection fraction regardless of chronic kidney disease status

Top-line Phase II Data for treatment of MASH

FDA Provides Full Approval to Praxbind, Specific Reversal Agent for Pradaxa

Boehringer Ingelheim announces comprehensive settlement of U.S. Pradaxa® (dabigatran etexilate mesylate) litigation

Boehringer Ingelheim and Lilly announce the CAROLINA cardiovascular outcome trial of Tradjenta met its primary endpoint of non-inferiority compared with glimepiride

U.S. FDA Grants Fast Track Designation to Empagliflozin for the Treatment of Chronic Heart Failure

Health disparities in Black and African Americans

Jardiance shows consistent cardio-renal benefits in adults with heart failure with left ventricular ejection fraction over 40% regardless of chronic kidney disease status

Improving Access to Clinical Trials

Diabetes

Boehringer Ingelheim grows faster than the pharmaceutical market for the tenth time in succession / continued high level of investment in research and development / market launch of five innovative medicines planned

Boehringer Ingelheim and OSE Immunotherapeutics Announce Global Immuno-Oncology Partnership to Develop a Pioneering Checkpoint Inhibitor for the Treatment of Advanced Solid Tumors

FDA Approves Praxbind® (idarucizumab), Specific Reversal Agent for Pradaxa® (dabigatran etexilate mesylate)

Jardiance® reduced risk of cardiovascular death in adults with type 2 diabetes and peripheral artery disease

IPF patients treated with Ofev® (nintedanib) versus placebo were twice as likely to have improved or stable lung function

PetPro Connect: Veterinary Medicine in the Digital Age